Bill To Revise US Subject Matter Patent Eligibility Standard Expected By 'Early Summer'

Senators emphasize need for legislative reform at IP subcommittee hearing; ask USPTO director Iancu how a drug can have 130 patents, alluding to Humira.

Capitol House

Tackling one of biopharma's top policy concerns, the leaders of the Senate Judiciary Committee's Intellectual Property Subcommittee are working on legislation to revise the standard for determining what inventions are eligible to be patented.

"Everyone knows the current standard is a mess and that is creating massive uncertainty for almost every single industry that relies on patent protections," Subcommittee Chairman Thom Tillis, R-NC, said at a March 13 hearing on oversight of the US Patent and Trademark Office

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Pink Sheet

Austria To Fine Companies For Violating New Drug Stockpiling Rule

 

A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By 

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.